http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2659200-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ea46551e141c1b71064d0cb4ae10877
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
filingDate 2017-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_144099502bc04744049201153b3bf9ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a66fb2298882cc294f780f5b6073b7f8
publicationDate 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2659200-C1
titleOfInvention Pharmaceutical composition containing alimamazine tartrate
abstract FIELD: pharmaceutics. n SUBSTANCE: invention relates to chemical-pharmaceutical industry and medicine. Pharmaceutical composition contains alimamazine tartrate and auxiliary components. As auxiliary components, microcrystalline cellulose, hypromellose, silica colloidal dioxide and magnesium stearate in the amounts indicated in the claims are selected. Pharmaceutical composition of alimamazine tartrate is in the form of a tablet coated with a film coating. n EFFECT: tablet according to invention provides a sustained release of alimamazine tartrate, while retaining advantages in the form of a short half-life; characterized by satisfactory stability, strength of more than 70 N, and an abrasion resistance of at least 98,5%. n 5 cl, 4 tbl, 5 ex
priorityDate 2017-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2384336-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2424807-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1152697-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007104969-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID72287
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4927
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496863
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492649
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491718
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493659
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447315
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449454525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322677

Total number of triples: 50.